These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 9922142)
1. Crystal structure of the complex between VEGF and a receptor-blocking peptide. Wiesmann C; Christinger HW; Cochran AG; Cunningham BC; Fairbrother WJ; Keenan CJ; Meng G; de Vos AM Biochemistry; 1998 Dec; 37(51):17765-72. PubMed ID: 9922142 [TBL] [Abstract][Full Text] [Related]
2. Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor. Pan B; Li B; Russell SJ; Tom JY; Cochran AG; Fairbrother WJ J Mol Biol; 2002 Feb; 316(3):769-87. PubMed ID: 11866530 [TBL] [Abstract][Full Text] [Related]
3. Solution structure of the VEGF-binding domain of Flt-1: comparison of its free and bound states. Starovasnik MA; Christinger HW; Wiesmann C; Champe MA; de Vos AM; Skelton NJ J Mol Biol; 1999 Oct; 293(3):531-44. PubMed ID: 10543948 [TBL] [Abstract][Full Text] [Related]
4. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Fairbrother WJ; Christinger HW; Cochran AG; Fuh G; Keenan CJ; Quan C; Shriver SK; Tom JY; Wells JA; Cunningham BC Biochemistry; 1998 Dec; 37(51):17754-64. PubMed ID: 9922141 [TBL] [Abstract][Full Text] [Related]
5. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Muller YA; Christinger HW; Keyt BA; de Vos AM Structure; 1997 Oct; 5(10):1325-38. PubMed ID: 9351807 [TBL] [Abstract][Full Text] [Related]
6. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Muller YA; Chen Y; Christinger HW; Li B; Cunningham BC; Lowman HB; de Vos AM Structure; 1998 Sep; 6(9):1153-67. PubMed ID: 9753694 [TBL] [Abstract][Full Text] [Related]
7. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Wiesmann C; Fuh G; Christinger HW; Eigenbrot C; Wells JA; de Vos AM Cell; 1997 Nov; 91(5):695-704. PubMed ID: 9393862 [TBL] [Abstract][Full Text] [Related]
9. Solution structure of the heparin-binding domain of vascular endothelial growth factor. Fairbrother WJ; Champe MA; Christinger HW; Keyt BA; Starovasnik MA Structure; 1998 May; 6(5):637-48. PubMed ID: 9634701 [TBL] [Abstract][Full Text] [Related]
10. Characterization of the VEGF binding site on the Flt-1 receptor. Herley MT; Yu Y; Whitney RG; Sato JD Biochem Biophys Res Commun; 1999 Sep; 262(3):731-8. PubMed ID: 10471394 [TBL] [Abstract][Full Text] [Related]
11. Crystallization of the receptor binding domain of vascular endothelial growth factor. Christinger HW; Muller YA; Berleau LT; Keyt BA; Cunningham BC; Ferrara N; de Vos AM Proteins; 1996 Nov; 26(3):353-7. PubMed ID: 8953654 [TBL] [Abstract][Full Text] [Related]
12. Computer modelling of the receptor-binding domains of VEGF and PIGF. Walsh TP; Grant GH Protein Eng; 1997 Apr; 10(4):389-98. PubMed ID: 9194163 [TBL] [Abstract][Full Text] [Related]
13. 1H, 13C, and 15N backbone assignment and secondary structure of the receptor-binding domain of vascular endothelial growth factor. Fairbrother WJ; Champe MA; Christinger HW; Keyt BA; Starovasnik MA Protein Sci; 1997 Oct; 6(10):2250-60. PubMed ID: 9336848 [TBL] [Abstract][Full Text] [Related]
14. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973 [TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: auto-paracrine role during endochondral bone formation. Carlevaro MF; Cermelli S; Cancedda R; Descalzi Cancedda F J Cell Sci; 2000 Jan; 113 ( Pt 1)():59-69. PubMed ID: 10591625 [TBL] [Abstract][Full Text] [Related]
16. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724 [TBL] [Abstract][Full Text] [Related]
17. The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 A resolution. Iyer S; Leonidas DD; Swaminathan GJ; Maglione D; Battisti M; Tucci M; Persico MG; Acharya KR J Biol Chem; 2001 Apr; 276(15):12153-61. PubMed ID: 11069911 [TBL] [Abstract][Full Text] [Related]
19. Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor/placenta growth factor receptor Flt-1 required for binding and structural stability. Davis-Smyth T; Presta LG; Ferrara N J Biol Chem; 1998 Feb; 273(6):3216-22. PubMed ID: 9452434 [TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Muller YA; Li B; Christinger HW; Wells JA; Cunningham BC; de Vos AM Proc Natl Acad Sci U S A; 1997 Jul; 94(14):7192-7. PubMed ID: 9207067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]